维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病的临床观察-中国药房

维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病的临床观察

请在关注微信后，向客服人员索取文件

篇名：	维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病的临床观察
TITLE：	Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia
摘要：	目的观察维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病（AML）的近期疗效和安全性。方法回顾性收集2022年10月至2023年11月我院收治的40例初诊AML患者资料，根据治疗方案分为观察组和对照组，每组20例。对照组患者给予注射用盐酸柔红霉素+注射用阿糖胞苷，观察组患者给予维奈克拉片+高三尖杉酯碱注射液+注射用阿糖胞苷。两组患者均以28d为1个周期，诱导化疗1个周期后评价近期疗效、微小残留病（MRD）阴性率、粒细胞缺乏持续时间、血小板计数（PLT）＜20×109L－1持续时间、悬浮红细胞输注量及血小板输注量，以及不良反应发生情况。结果观察组患者的完全缓解或完全缓解伴血液学不完全恢复（CR/CRi）率显著高于对照组（P＜0.05），且在CR/CRi患者中，观察组患者的MRD阴性率也显著高于对照组（P＜0.05）；但在低、中、高危患者中，两组患者的CR/CRi率比较，差异均无统计学意义（P＞0.05）。两组患者的粒细胞缺乏持续时间、PLT＜20×109L－1持续时间、悬浮红细胞输注量、血小板输注量、血液学毒性反应发生率及非血液学毒性反应发生率比较，差异均无统计学意义（P＞0.05）。结论维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗AML的近期疗效和安全性较均好。
ABSTRACT：	OBJECTIVE To observe the short-term efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia （AML）. METHODS The data of 40 newly diagnosed AML patients admitted to our hospital from October 2022 to November 2023 were retrospectively collected and divided into observation group and control group according to treatment plan， with 20 cases in each group. The patients in the control group were given Daunorubicin hydrochloride for injection+Cytarabine for injection， and the patients in the observation group were given Venetoclax tablets+ Homoharringtonine injection+Cytarabine for injection. The patients in both groups were given relevant medicine， with 28 days as one cycle. The short-term efficacy， negative rate of minimal residual disease （MRD）， duration of granulocyte deficiency， duration of platelet （PLT）＜20×109 L－1， transfusion volume of suspended red blood cells and platelet， and the occurrence of adverse drug reactions were evaluated in both groups after 1 cycle of induction chemotherapy. RESULTS The complete remission or complete remission with incomplete hematologic recovery （CR/CRi） rate in the observation group was significantly higher than control group （P＜0.05）， and the negative rate of MRD in the observation group was also significantly higher than control group （P＜0.05）. However， in low-， medium- and high-risk patients， there was no statistical significance in CR/CRi rates between the two groups （P＞0.05）. There were no significant differences in the duration of agranulocytosis， the duration of PLT ＜20×109 L－1， the amount of suspended red blood cell transfusion， the amount of platelet transfusion， the incidence of hematologic toxicity and the incidence of non-hematologic toxicity between 2 groups （P＞0.05）. CONCLUSIONS Venetoclax combined with homoharringtonine and cytarabine show good short-term efficacy and safety in the treatment of AML.
期刊：	2024年第35卷第14期
作者：	周玲；彭秋媛；赵攀；魏锦；林晓静；邹兴立；罗文丰；王静；谢坤莹；李向龙；刘洋；倪勋
AUTHORS：	ZHOU Ling，PENG Qiuyuan，ZHAO Pan，WEI Jin， LIN Xiaojing，ZOU Xingli，LUO Wenfeng，WANG Jing，XIE Kunying，LI Xianglong，LIU Yang，NI Xun
关键字：	急性髓系白血病；维奈克拉；高三尖杉酯碱；阿糖胞苷；疗效；安全性
KEYWORDS：	acute myeloid leukemia； venetoclax；
阅读数：	5 次
本月下载数：	0 次

* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！